Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Recommendation of “Hold” from Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received a consensus rating of “Hold” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $10.00.

ZNTL has been the topic of a number of recent research reports. Guggenheim reduced their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Finally, Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday.

Zentalis Pharmaceuticals Stock Down 3.5 %

Zentalis Pharmaceuticals stock opened at $2.22 on Friday. Zentalis Pharmaceuticals has a 52 week low of $2.13 and a 52 week high of $18.07. The firm’s 50-day simple moving average is $3.05 and its 200 day simple moving average is $3.34. The firm has a market capitalization of $158.20 million, a PE ratio of -0.89 and a beta of 1.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36. On average, research analysts expect that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 115.6% during the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after acquiring an additional 30,240 shares during the period. Barclays PLC lifted its holdings in shares of Zentalis Pharmaceuticals by 18.5% during the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after acquiring an additional 11,748 shares during the period. XTX Topco Ltd raised its stake in Zentalis Pharmaceuticals by 8.7% during the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock worth $714,000 after purchasing an additional 15,597 shares during the period. Quarry LP purchased a new position in Zentalis Pharmaceuticals during the third quarter worth approximately $55,000. Finally, Paloma Partners Management Co purchased a new position in Zentalis Pharmaceuticals during the third quarter worth approximately $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.